CIRION acquires cutting-edge technology platform for bioanalysis



    Electrochemiluminescent assays are more sensitive, precise and cost-
    effective over conventional methods

    LAVAL, QC, Oct. 16 /CNW Telbec/ - Laval-based provider of Central
Laboratory and R&D Services to the biotechnology and pharmaceutical sectors,
CIRION Clinical Trial Services Inc. has expanded its research capacity through
the purchase of the latest technology.
    CIRION's ongoing commitment to supporting its clients' projects through
the latest technological advancements was highlighted at BioContact Québec's
2008 Biopharmaceutical Partnership Symposium held in Québec City October 1-3,
2008.
    In a corporate overview, CIRION's Vice President of Business Development,
Fraser Day, announced the acquisition of a new cutting edge technology
platform to its extensive laboratory equipment. The state-of-the art Meso
Scale SECTOR(TM) Imager 6000 reader is the newest member of the award-winning
SECTOR(TM) Imager product line from Meso Scale Discovery headquartered in
Gaithersburg, Maryland.
    The Meso Scale platform utilizes electrochemiluminescent (ECL) detection
to measure binding interactions between molecules, an integral part of the
identification and development of protein-based drugs.
    The ECL method offers a number of advantages over conventional
immunoassay (ELISA, RIA) methods, such as high sensitivity and reliability,
high throughput, lower sample volume requirements, greater speed of execution
and the ability to measure multiple biomarkers in a single specimen
simultaneously.
    CIRION has been working with the previous generation of the Meso Scale
platform and therefore, its clients can benefit from the expertise of trained
scientists for the development of customized bioassays and solutions to
clinical development challenges.

    About CIRION

    CIRION is a leading provider of Central Laboratory services for clinical
studies and is well equipped to test drug candidates to accelerate clinical
trials. The company offers a complete range of project management and
logistical services, a broad portfolio of safety and specialized assays and
development & validation services. CIRION has 12 years experience in
developing assays and writing GLP procedures acceptable to regulatory
agencies. The company is accredited from the College of American Pathologists
(CAP) and the Center for Disease Control (CDC). For more information, please
visit <a href="http://www.cirion.com">www.cirion.com</a>.




For further information:

For further information: Lorella Di Donato, (450) 688-6445,
didonatol@cirion.com

Organization Profile

CIRION CLINICAL TRIAL SERVICES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890